In the 2025 fiscal year, Euroapi's revenues declined by 7% to €848.2 million, while EBITDA improved significantly, rising from -€43.6 million to €9.9 million. This strong performance is all the more notable as it includes €58.8 million in non-recurring charges related to the Focus 2027 plan.
At the same time, gross margin also increased, reaching €144.8 million compared to €142.4 million a year earlier.
Meanwhile, net cash position at the end of 2025 stood at €68.2 million, a marked improvement from the €24.6 million recorded at the end of 2024.
However, net loss widened significantly, reaching €211.2 million compared to €130.6 million a year earlier.
For the current fiscal year, Euroapi is forecasting a revenue decline of around 10% on a comparable basis, due to the negative impact of portfolio rationalization, decreased demand from Sanofi, and the termination of contracts.
The core EBITDA margin is expected to remain broadly stable. Improvements in industrial efficiency and continued reductions in OPEX will be more than offset by unfavorable absorption of fixed costs resulting from lower volumes. EBITDA is also expected to be impacted by restructuring costs.
EUROAPI specializes in the development and manufacture of active pharmaceutical ingredients on behalf of healthcare industries. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc.
EUROAPI has 5 production sites located in France (2), Germany, Italy and Hungary.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
